Integer (ITGR) Citi Annual Global Healthcare Conference 2025 summary

Strategic direction and market positioning

• Focused on high-growth medtech markets: electrophysiology, neurovascular, structural heart, and neuromodulation.

• Strategy centers on building differentiated engineering and manufacturing capabilities, engaging early in product development, and targeted tuck-in M&A.

• Strong, growing pipeline with 80% of development sales in fastest-growing markets.

• Vision to be the most innovative CDMO globally, leveraging both organic growth and acquisitions.

• Portfolio diversification limits revenue risk from underperforming products.

Financial outlook and recent actions

• Core business expected to grow 4%-7% in 2026, in line with or slightly above market rates.

• Three products face adoption headwinds in 2026, causing a temporary three-quarter revenue and margin pressure.

• Anticipates return to market growth in H2 2026 and above-market growth in 2027, driven by new product launches.

• Initiated a $200 million share repurchase program for the first time, reflecting confidence in fundamentals and undervalued stock.

• Margin expansion relies on manufacturing efficiencies and disciplined fixed cost management during the air pocket.

Product development and customer engagement

• Early engagement with customers in product design and development is key to long-term partnerships.

• Product development cycles typically span several years, with risk adjustments for launch timing and regulatory factors.

• Manufacturing expertise and scalability are core competencies, with a focus on delivery systems in structural heart and other complex devices.

• AI integration in manufacturing and product development is a growing focus, supported by data-rich automation systems.